Ubs Group Ag An2 Therapeutics, Inc. Transaction History

Ubs Group Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.93 - $3.76 $4,035 - $7,862	-2,091 Reduced 10.68%	17,483 $37,000
Q1 2024 May 13, 2024	BUY	$2.78 - $21.53 $54,415 - $421,428	19,574 New	19,574 $63,000
Q3 2023 Nov 09, 2023	SELL	$7.58 - $16.08 $65,392 - $138,722	-8,627 Reduced 17.37%	41,046 $660,000
Q2 2023 Aug 11, 2023	SELL	$5.06 - $9.91 $12,913 - $25,290	-2,552 Reduced 4.89%	49,673 $422,000
Q1 2023 May 12, 2023	BUY	$7.94 - $15.6 $6,113 - $12,012	770 Added 1.5%	52,225 $515,000
Q4 2022 Feb 08, 2023	BUY	$8.51 - $19.69 $190,181 - $440,032	22,348 Added 76.78%	51,455 $490,000
Q3 2022 Nov 10, 2022	SELL	$7.61 - $22.29 $146,568 - $429,305	-19,260 Reduced 39.82%	29,107 $506,000
Q2 2022 Aug 10, 2022	BUY	$7.7 - $18.82 $363,509 - $888,473	47,209 Added 4076.77%	48,367 $375,000
Q1 2022 May 16, 2022	BUY	$15.0 - $15.4 $17,370 - $17,833	1,158 New	1,158 $17,000

13.5M

Ticker ANTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,402,700
Market Cap $26M
Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.